Options of modern anti-relapse therapy for urinary tract infections in children: CRUTIL trial
DOI:
https://doi.org/10.22141/2307-1257.8.2.2019.166663Keywords:
recurrent urinary tract infections in children, industrial bacterial lysates, Urivac, Uro-Vaxom, follow-up in urinary tract infectionsAbstract
Background. Recurrent urinary tract infection (UTI) is a serious problem in pediatric nephrology, affecting the quality of life and increasing the burden on the health system. Consideration of individual factors and the development of approaches to anti-relapse therapy, especially in children without apparent objective reasons for the relapse of infection, is an urgent task. Materials and methods. A prospective, multicentre, randomized, parallel-group, open-label CRUTIL (Children’s Recurrent Urinary Tract Infections on bacterial Lysate) study was conducted, it included 83 children aged 3 to 15 years (8.0 ± 2.2 years) with recurrent UTI. The children were randomized into 3 groups: the first one — 22 patients who received supplementary therapy with Urivac lysate, the second one — 28 children who received supplementary therapy with Uro-Vaxom lysate, and the third group (controls) — 33 patients who received standard therapy. Duration of immunoactive therapy was 6 months, patients of these groups also received anti-relapse treatment with a single dose of urinary antiseptic at bedtime for 18 months; follow-up was 24 months. Results. In the first group of children who received Urivac, a 6-valent vaccine from bacterial lysates, a non-recurrent course to the end of the study was observed in 19 patients (87 %). In the group receiving Uro-Vaxom bacterial monolysates, 20 children (72 %) had non-recurrent course (odds ratio (OR) = 2.5; P > 0.05; the minimum expected effect was 4.84). Among those who did not receive urinary antiseptic at bedtime and bacterial lysates, the non-recurrent course was reported in 13 children (40 %) (P ≤ 0.05, OR = 0.26 with a 6-valent vaccine group). A 15% improvement in the effectiveness was obtained due to elimination of Pseudomonas aeruginosa and Enterococcus faecalis when using a 6-valent bacterial lysate. Subsequently, from 24 to 30 months of follow-up, 3 more children in the Uro-Vaxom group had a relapse (P ≤ 0.05 with the Urivac group). Conclusions. Bacterial lysates significantly increase the effectiveness of therapy for recurrent urinary tract infections in children. The best results in the formation of a non-recurrent course of relapsing UTI were obtained when using a prophylactic dose of urinary antiseptic once at bedtime and a 6-valent Urivac vaccine.
Downloads
References
DynaMed Plus. Record No. T115591, Urinary tract infection (UTI) in children. Available from: https://www.dynamed.com/topics/dmp~AN~T115591. Accessed: November 30, 2018.
Radmayr C, Bogaert G, Dogan HS, et al. EAU Guidelines: Paediatric Urology. Available from: https://uroweb.org/guideline/paediatric-urology/.
Kass EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians. 1956;69:56-64.
Ivanov DD, Korg OM. Nefrologija u praktyci simejnogo likarja [Nephrology in the practice of a family doctor]. Donetsk: Publisher Zaslavsky OYu; 2014. 520 p. (in Ukrainian).
World Health Organization. Informed Consent Form Templates. Available from: https://www.who.int/rpc/research_ethics/informed_consent/en/.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 D.D. Ivanov, T.P. Ivanova, O.G. Fedorenko, S.V. Kushnirenko, M.D. Ivanova
This work is licensed under a Creative Commons Attribution 4.0 International License.